The content is available as a PDF (113.5 KB).
Footnotes
Este trabajo ha obtenido el premio a la mejor comunicación oral en las IX Jornadas de Residentes de la Sociedad Madrileña de Medicina Familiar y Comunitaria. Madrid, 9 de marzo de 2007.
Bibliografía
- 1.Mintzes B. Disease mongering in drug promotion: do governments have a regulatory role? PLoS Med. 2006;3:e198. doi: 10.1371/journal.pmed.0030198. [Epub 2006 Abr 11] [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Gardasil. European public assessment report. Scientific discussion [citado 7 Mar 2007]. Disponible en: www.emea.europa.eu/humandocs/PDFs/EPAR/gardasil/070306en6.pdf
- 3.Pichon-Rivière A, Augustovski F, Alcaraz A, Bardach A, Colantonio L, García S, et al. Eficacia de la vacuna para el virus del papiloma humano (HPV). Buenos Aires: Instituto de Efectividad Clínica y Sanitaria. Documentos de evaluación de tecnologías sanitarias. Informe de respuesta rápida 86. 2006 Oct [citado 7 Mar 2007]. Disponible en: www.iecs.org.ar/iecs-visor-publicacion.php?cod_publicacion=510
- 4.Schmiedeskamp M.R., Kockler D.R. Human papillomavirus vaccines. Ann Pharmacother. 2006;40:1344–1352. doi: 10.1345/aph.1G723. [DOI] [PubMed] [Google Scholar]
- 5.Committee on Adolescent Health Care; ACOG Working Group on Immunization American College of Obstetricians and Gynecologists Committee Opinion No. 344. Human papillomavirus vaccination. Obstet Gynecol. 2006;108:699–705. doi: 10.1097/00006250-200609000-00047. [DOI] [PubMed] [Google Scholar]
- 6.American Academy of Pediatrics Committee on Infectious Diseases Recommended immunization schedules for children and adolescents–United States, 2007. Pediatrics. 2007;119:207–208. doi: 10.1542/peds.2006-3309. [DOI] [PubMed] [Google Scholar]
- 7.Harper DM. Human papillomavirus vaccines. UpToDate Online 15.1.Waltham (MA): UpToDate (Estados Unidos). C2007 [actualizado 8 Sep 2006; citado 7 Mar 2007]. Disponible en: www.utdol.com
- 8.Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–278. doi: 10.1016/S1470-2045(05)70101-7. [DOI] [PubMed] [Google Scholar]
- 9.Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006;24:5571–5583. doi: 10.1016/j.vaccine.2006.04.068. [DOI] [PubMed] [Google Scholar]
- 10.Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006;107:18–27. doi: 10.1097/01.AOG.0000192397.41191.fb. Erratum in: Obstet Gynecol. 2006;107:1425. [DOI] [PubMed] [Google Scholar]
- 11.Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459–1466. doi: 10.1038/sj.bjc.6603469. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Advisory Committee on Immunization Practices. ACIP provisional recommendations for the use of quadrivalent HPV vaccine. 2006 Jun [citado 7 Mar 2007]. Disponible en: www.cdc.gov/nip/recs/provisional_recs/hpv.pdf
- 13.National Advisory Committee on Immunization Statement on human papillomavirus vaccine. Can Commun Dis Rep. 2007;33:1–32. [PubMed] [Google Scholar]
- 14.FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–1927. doi: 10.1056/NEJMoa061741. [DOI] [PubMed] [Google Scholar]
- 15.Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–1943. doi: 10.1056/NEJMoa061760. [DOI] [PubMed] [Google Scholar]
- 16.Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization and Practices (ACIP) MMWR Recomm Rep. 2007;56:1–24. [PubMed] [Google Scholar]
- 17.Hunter MI, Holschneider CH. Cervical intraepithelial neoplasia: Etiology, diagnosis, and natural history. UpToDate Online 15.1. Waltham (MA): UpToDate (Estados Unidos). C2007 [actualizado 20 Oct 2006; citado 7 Mar 2007]. Disponible en: www.utdol.com
- 18.Schiffman M., Castle P.E. The promise of global cervical-cancer prevention. N Engl J Med. 2005;353:2101–2104. doi: 10.1056/NEJMp058171. [DOI] [PubMed] [Google Scholar]
- 19.Spier R.E. Ethical aspects of vaccines and vaccination. Vaccine. 1998;16:1788–1794. doi: 10.1016/S0264-410X(98)00169-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. version 2.0, IARCPress, Lyon, 2004 [citado 7 Mar 2007]. Disponible en: www-dep.iarc.fr
- 21.Marzo-Castillejo M., Bellas-Beceiro B., Nuin-Villanueva M., Cierco-Peguera P., Moreno-Baquerano M., Rubio-Toledano L. Grupo de Prevención del Cáncer del PAPPS. Actualizaciones 2005. Aten Primaria. 2005;36(Supl 2):S47–S65. [Google Scholar]
- 22.Pass F. Vaccines for latent viruses. J Am Acad Dermatol. 1988;18:224–226. doi: 10.1016/s0190-9622(88)70033-x. [DOI] [PubMed] [Google Scholar]
- 23.Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. doi: 10.3322/canjclin.55.2.74. [DOI] [PubMed] [Google Scholar]